



Article  
scientifique

Revue de la  
littérature

2018

Accepted  
version

Open  
Access

This is an author manuscript post-peer-reviewing (accepted version) of the original publication. The layout of the published version may differ .

---

Methods to validate Hsp90 inhibitor specificity, to identify off-target effects,  
and to rethink approaches for further clinical development

---

Neckers, Len; Blagg, Brian; Haystead, Timothy; Trepel, Jane B.; Whitesell, Luke; Picard, Didier

**How to cite**

NECKERS, Len et al. Methods to validate Hsp90 inhibitor specificity, to identify off-target effects, and to rethink approaches for further clinical development. In: Cell Stress and Chaperones, 2018, vol. 23, n° 4, p. 467–482. doi: 10.1007/s12192-018-0877-2

This publication URL: <https://archive-ouverte.unige.ch/unige:114490>

Publication DOI: [10.1007/s12192-018-0877-2](https://doi.org/10.1007/s12192-018-0877-2)

Methods to validate Hsp90 inhibitor specificity, to identify off-target effects  
and to rethink approaches for further clinical development

Len Neckers<sup>1\*</sup>, Brian Blagg<sup>2</sup>, Timothy Haystead<sup>3</sup>, Jane B. Trepel<sup>4</sup>, Luke  
Whitesell<sup>5#</sup>, and Didier Picard<sup>6\*</sup>

<sup>1</sup> Urologic Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA

<sup>2</sup> Warren Family Research Center for Drug Discovery and Development, University of  
Notre Dame, Notre Dame, IN 46556, USA

<sup>3</sup> Department of Pharmacology and Cancer Biology, Duke University, Durham, NC  
27710, USA

<sup>4</sup> Developmental Therapeutics Branch, National Cancer Institute, Bethesda, MD 20892,  
USA

<sup>5</sup> Whitehead Institute, Cambridge, MA 02142, USA

<sup>6</sup> Département de Biologie Cellulaire, Université de Genève, 1211 Geneva 4,  
Switzerland

\* corresponding authors (len@helix.nih.gov; didier.picard@unige.ch)

# current address: Department of Molecular Genetics, University of Toronto, Toronto, ON  
M5G 1M1, Canada

## **Abstract**

The molecular chaperone Hsp90 is one component of a highly complex and interactive cellular proteostasis network (PN) that participates in protein folding, directs misfolded and damaged proteins for destruction, and participates in regulating cellular transcriptional responses to environmental stress, thus promoting cell and organismal survival. Over the last 20 years it has become clear that various disease states, including cancer, neurodegeneration, metabolic disorders, and infection by diverse microbes impact the PN. Among PN components, Hsp90 was among the first to be pharmacologically targeted with small molecules. While the number of Hsp90 inhibitors described in the literature has dramatically increased since the first such small molecule was described in 1994, it has become increasingly apparent that not all of these agents have been sufficiently validated for specificity, mechanism of action and lack of off-target effects. Given the less than expected activity of Hsp90 inhibitors in cancer-related human clinical trials, a re-evaluation of potentially confounding off-target effects, as well as confidence in target specificity and mechanism of action, is warranted. In this commentary, we provide feasible approaches to achieve these goals and we discuss additional considerations to improve the clinical efficacy of Hsp90 inhibitors in treating cancer and other diseases.

## **Introduction**

Maintenance of cellular protein homeostasis (also termed proteostasis) is now recognized to be of major importance for cell and organismal viability. In aging, or in various neurodegenerative diseases, proteostasis is generally compromised as a result of either reduced expression or inactivation of one or more components of the cellular proteostasis network (PN). These components (many of which serve in more than one capacity) include the proteasome, autophagy-related proteins, and molecular chaperones, notably Hsp90. Cancer cells, because of their genetic instability, frequent aneuploidy, and abundance of mutated/misfolded proteins, are highly dependent on the

PN, components of which (e.g., Hsp90) are frequently upregulated compared to normal cells. Inhibition of one molecular component is akin to plucking a strand within a spider's web, as the frequent result is upregulation of and potential compensation by other parts of the network. Thus, in developing and validating pharmacologic inhibitors of individual PN molecules, it is critically important to provide convincing evidence of target specificity and to document off-target effects where possible. This is particularly relevant in the case of inhibitors of Hsp90-family members, because these molecular chaperones play complex and multi-faceted roles in cellular proteostasis (Fig. 1). To further complicate matters, the Hsp90 family includes two cytoplasmic/nuclear isoforms, constitutively expressed Hsp90 $\beta$  and stress-induced Hsp90 $\alpha$ , as well as isoforms restricted to the endoplasmic reticulum and mitochondria (Grp94 and Trap1, respectively). Thus, inhibiting "Hsp90" could reflect simultaneous inhibition of all or some of these family members, with potentially distinct cellular consequences. The Hsp90 family shares a highly conserved N-terminal domain containing an ATP-binding pocket that is the site targeted by all Hsp90 inhibitors that have been clinically evaluated in cancer patients at this writing. A second, C-terminal druggable site has also been identified. Although inhibitors targeted to this site have been developed, this C-terminal drug-binding site is less well characterized than is the N-terminal ATP-binding pocket (Fig. 2). However, one C-terminal inhibitor, RTA901 (Reata Pharmaceuticals) is currently in a phase 1 clinical trial (clinicaltrials.gov identifier: NCT02666963) for non-cancer indications. RTA901 is based on the novobiocin analog KU32 and has shown favorable activity in a range of preclinical models of neurodegeneration and neuroprotection, including diabetic neuropathy and neural inflammation (Ma et al 2014).

Although others have questioned the specificity of N-terminal domain inhibitors in comparison to compounds targeted to the C-terminal domain (Wang et al 2017), one must be very careful to apply the same basic pharmacological principles of potency and specificity to the validation of all putative Hsp90 inhibitors. For example, little information is available concerning either the preference of inhibitors targeted to the C-terminal domain for the four Hsp90 family isoforms or a careful examination of their possible off-target effects. This commentary will discuss feasible experimental approaches for

validating the binding specificity of inhibitors that target either of these sites, while also describing techniques to identify and to characterize possible off-target effects manifested by these agents. Finally, we will propose a new paradigm for more optimal use of Hsp90 inhibitors in cancer therapy – one that recognizes Hsp90 is but one node in the cellular PN of both a cancer and its host.

## **Authentication and validation of ATP-competitive inhibitors targeting the N-terminal domain**

A survey of the current literature defines 5 distinct chemical scaffolds that have given rise to ATP-competitive inhibitors of Hsp90 and its paralogs Grp94 and Trap1 (Shi et al 2012; Kitson and Moody 2013; Gewirth 2016). Fig. 3 provides examples of each of these core scaffolds, which include purine-, benzoquinone ansamycin-, resorcinol-, indoline- and tropane-based structures. From these core structures many active analogs have been derived in structure-activity relationship (SAR) analysis campaigns designed to improve pharmacological properties *in vivo*. The structural diversity of these scaffolds is somewhat extraordinary within the context of ATP-competitive inhibitors targeting a single family of proteins such as Hsp90. Such structural diversity against a single conserved domain is rare. The extensively studied protein kinase family has yet to provide examples of multiple inhibitor classes that are as selective for an individual target as those targeting the Hsp90 family. Importantly, an extensive body of independently evaluated literature has established selectivity parameters and molecular insights on which one can build to define essential criteria for the validation of any putative new ATP-competitive agent as a *bona fide* inhibitor of the Hsp90 family. These criteria include a solved co-crystal structure, development of active and inactive analogs, affinity reagents, ATP-competition studies, and measurable effects on one or more Hsp90 client proteins (proteins that directly interact with and depend on Hsp90 for stability and function).

### ***Co-crystal structures***

Co-crystal structures of geldanamycin (GA) bound to Hsp90 appeared simultaneously in 1997 and revealed a drug binding pocket in the N-terminal domain that was highly conserved among Hsp90 family members across species (Prodromou et al 1997; Stebbins et al 1997). Based on the work of Toft and co-workers and the Pearl group, this pocket was quickly confirmed as an ATP binding domain (Grenert et al 1997; Prodromou et al 1997). Shortly thereafter, the second natural product Hsp90 inhibitor, radicicol, was found to occupy the same nucleotide binding pocket (Roe et al 1999). A similar mode of nucleotide binding was observed in the complete structure of Grp94 by Gewirth and colleagues (Soldano et al 2003). These structures showed the unique and unexpected orientation of the purine within the active site and they defined the essential contacts made with individual residues in the ATP- binding pocket. The orientation of the nucleotide is distinct from that of other classical ATPases and chaperones such as Heat shock protein 70 (Alderson et al 2016). Fig. 4 provides co-crystal structures for all 5 scaffolds shown in Fig. 3. Each of these co-crystal structures provide a molecular basis for the specificity of a particular scaffold for Hsp90 family members. With these structures, one can directly test the importance of various interactions by creating mutations of the protein or by chemically modifying the inhibitor. There are multiple examples of such studies in the literature (Chiosis et al 2003; Wright et al 2004; He et al 2006; Immormino et al 2006; Eccles et al 2008; Fadden et al 2010; Duerfeldt et al 2012; Gewirth 2016). Other methods such as NMR or cryo-electron microscopy can serve as alternative biophysical approaches to interrogate and to validate small molecule – Hsp90 interactions (Verba et al 2016).

### ***Analog development***

If one reviews the history of all small molecule inhibitors recognized as selective for their targets, from natural products to fully synthetic molecules, invariably there is an accompanying literature of related active and inactive analogs. In this context, the five Hsp90-targeting scaffolds stack up well. From a pharmacologist's or chemical biologist's perspective, analogs of an active molecule are the equivalent (if not better) than

mutation or knockout of the target itself. Unlike the genetic approach, active and inactive analogs can be tested alongside the original molecule across every relevant cell type and in any animal. Co-crystal structures provide a direct path for the development of analogs because they define the essential amino acid contacts between the inhibitor and binding site. Typically, one desires analogs without large substitutions because these could affect target specificity and bioavailability. For example, addition of a dimethyl group at the core amine of the SNX scaffold (see Fig. 3) reduces the affinity of the molecule for Hsp90 by 3 logs. The molecule no longer competes with ATP nor affects the stability of HER2, a highly dependent client of Hsp90 (Crowe et al 2017). Hsp90 inhibitors that do not have a history of analog development should be viewed with caution, since it is likely that their mechanisms of action (and potential for promiscuous off-target effects) are poorly defined. As a general rule, second generation fully synthetic Hsp90 inhibitors seem to have fewer off target effects compared to natural products such as GA and radicicol (see below). This is likely due to the fact that second generation inhibitors have been designed expressly to inhibit Hsp90 and are smaller and structurally simpler than the natural products.

### ***Affinity reagents***

A standard approach to defining the targets of a molecule is affinity purification. The experimental question is whether, if one attaches the molecule to a resin (e.g. Sepharose) or affinity tag (e.g. biotin), can one recover the expected target or its close paralogs – and nothing else - from a biological milieu. Affinity methods are valid means for defining selectivity of any Hsp90 inhibitor if one applies the following criteria. First, when immobilizing the molecule to a resin or coupling it to another handle such as biotin, the tether must be attached to a solvent-accessible region of the inhibitor based on the co-crystal structure; second, one must demonstrate competitive recovery of Hsp90 using either the free ligand, ATP, or another structurally distinct Hsp90 inhibitor sharing the same binding site. Understanding the point of attachment is vital to prevent steric hindrance by commonly used tethers (such as polyethylene based tethers). The choice of the tether is critical if one wants to minimize non-specific binding to the affinity matrix

itself. It is widely known that all proteins tend to stick to all types of surfaces by ionic and non-ionic interactions. Even very stringent washes with high salt or detergents often do not overcome these interactions. Therefore, the choice of both resin and tether are crucial, as are adequate competitive-binding data to demonstrate that Hsp90 or other proteins bound to an affinity matrix are retained by a specific interaction (for an example, see Hughes et al 2012).

### ***Inhibition of ATP binding and/or ATPase activity***

All five scaffolds illustrated in Fig. 3 are known competitive inhibitors of ATP binding to Hsp90. This characteristic can be used to validate these agents as follows: measuring ATPase activity in the presence of increasing concentrations of inhibitor using purified protein; elution from  $\gamma$ -phosphate linked ATP resin in the presence of increasing inhibitor concentrations; assessing inhibitor impact on thermal stability of Hsp90 protein. Most cell-active Hsp90 inhibitors would be expected to have low nM potency in an ATPase inhibition assay. Purified native Hsp90 has extremely low ATPase activity and requires additional co-factors to stimulate this activity such as the co-chaperone Aha1. To avoid this issue,  $\gamma$ -phosphate linked ATP-Sepharose provides a relatively simple way to capture Hsp90 in native or recombinant form and to measure the affinity and selectivity of an Hsp90 inhibitor (see also Grenert et al 1997; Fadden et al 2010). Assessment of thermal stability is increasingly emerging as a preferred method for evaluation of drug binding to target proteins. Nucleotide binding pockets are large and generally, when they are occupied by either nucleotide or a potent inhibitor, the protein becomes more stable to thermal denaturation, shifting its melting temperature ( $T_m$ ) by 10 °C or greater. For example, the SNX analog HS-10 shifts the  $T_m$  of native purified pig mammary Hsp90 and Grp94 by 11°C from 45°C to 56°C (Crowe et al 2017). This assay can be performed in a standard thermocycler, permitting many potential small molecule interactors to be assessed in parallel. Concentration-dependent shifts in  $T_m$  are directly proportional to the relative affinity of an inhibitor for its target.

An essential test for an Hsp90 inhibitor is to show potent intracellular activity as monitored by effects on established clients that are known to be highly sensitive to Hsp90 inhibition. One of the best characterized and most sensitive Hsp90 clients is HER2 (Trepel et al 2010), an oncogenic receptor tyrosine kinase that is highly expressed in some breast cancer cell lines. The effects of an Hsp90 inhibitor on levels of this protein can simply be followed by immunoblotting. Typically, cells expressing a known client of interest are incubated with increasing concentrations of an active and, if available, inactive analog. Cells are lysed after 6 - 24 hours (short exposure times are preferred as these are less likely to provide time for indirect or off-target effects) and immunoblotted with specific antibodies to the client protein. This method is adaptable to flow cytometry, especially if the client is expressed on the cell surface. Other highly sensitive Hsp90 kinase clients include mutated ALK, v-Src and Cdk4. Since N-terminal Hsp90 inhibitors promote rapid ubiquitination of most client proteins that is detectable by western blot even before depletion of the client protein itself (within 15 minutes of drug exposure in the case of HER2) (Mimnaugh et al 1996), immunoprecipitation of the client protein followed by western blotting for associated polyubiquitin chains is a valuable alternative or confirmatory approach to validate on-target activity.

## **Authentication and validation of competitive inhibitors targeting the C-terminal domain**

Hsp90 C-terminal inhibitors impair Hsp90 molecular chaperone function by binding at or near its C-terminal dimerization domain and have been used as evidence for a putative second nucleotide-binding pocket within the protein (Marcu et al 2000a; Marcu et al 2000b; Allan et al 2006; Matts et al 2011b). Probably owing to the flexible nature of this binding pocket, a co-crystal structure of Hsp90 with a bound C-terminal inhibitor has yet to be solved. As a result, this criterion cannot be used as validation of Hsp90 C-terminal inhibitor binding. Instead, researchers have relied upon affinity chromatography and proteolytic fingerprinting to evaluate whether a compound binds the Hsp90 C-terminal domain (Marcu et al 2000a; Marcu et al 2000b; Matts and Manjarrez 2009; Yin et al

2009; Matts et al 2011a). As the antibiotic novobiocin is the prototypical C-terminal inhibitor, proposed inhibitors can be assayed for their ability to elute Hsp90 from immobilized novobiocin (Yin et al 2009; Matts et al 2011a). In addition, compounds can be similarly investigated for their ability to inhibit binding of the C-terminal fragment to immobilized ATP (Marcu et al., 2000a; Yin et al 2009). Alternatively, once initial SARs for a new molecule have been defined, an affinity tag can be utilized to immobilize the proposed inhibitor, as has been done for novobiocin and inhibitors targeting the N-terminal domain (see above). Researchers can then confirm binding to a C-terminal fragment of Hsp90 and test whether the protein can be eluted by increasing concentrations of soluble inhibitor (Marcu et al 2000b; Yin et al 2009). Finally, a proteolytic footprint of Hsp90 produced upon incubation with the inhibitor should be used for final confirmation to determine whether it protects the same amino acids from trypsinolysis as that observed for novobiocin (Yun et al 2004). Although, to our knowledge, thermal stability techniques have not yet been applied to study C-terminal inhibitors, these also may prove useful as a complement to proteolytic footprinting.

Generally speaking, once binding to the Hsp90 C-terminus has been established, C-terminal inhibitors can be assessed for cellular activity by (1) evaluating their ability to inhibit Hsp90 immunoprecipitation, (2) examining the degradation of Hsp90-dependent client proteins, (3) preventing C-terminal dimerization of two Hsp90 protomers, and (4) inhibiting Hsp90-dependent biochemical refolding activity. Specifically, C-terminal inhibitors inhibit the immunoprecipitation of Hsp90 by the mouse monoclonal antibody AC88, whose epitope is within the Hsp90 C-terminal domain (Yun et al 2004). Finally, compounds can be evaluated for their ability to inhibit the Hsp90-dependent refolding of denatured luciferase or for their ability to prevent aggregation of thermally denatured citrate synthase (Buchner et al 1998; Galam et al 2007; Matts et al 2011a; Sadikot et al 2013). In the case of luciferase, care must be taken to control for possible direct (e.g., chaperone-independent) inhibition of luciferase by the compound in question.

## **Distinguishing off-target effects from secondary effects of Hsp90 inhibitors**

### ***Known off-target effects***

There is a tendency to forget that small molecule inhibitors are chemicals. As chemicals they may have multiple cellular targets, undergo metabolic conversion and generate toxic intermediates. In the case of Hsp90 inhibitors this is a particularly important consideration, since the molecular chaperone affects many downstream signaling pathways, some of which may be more or less active in distinct cell systems. Clearly, on-target Hsp90 inhibition is by definition, functionally pleiotropic. Thus, for this discussion, the term "off-target effects" will be used for direct effects of Hsp90 inhibitors on unrelated molecular targets and non-specific chemical effects. The potentially unwanted inhibition of other Hsp90 isoforms, such as the mitochondrial homolog Trap1 or the endoplasmic reticulum isoform Grp94, by a particular inhibitor will not be considered an off-target effect for the purposes of this commentary. Indeed, although Hsp90 isoform-selective inhibitors are beginning to emerge (Chan et al 2012; Duerfeldt et al 2012; Hughes et al 2012; Ye et al 2015; Yim et al 2016), the commonly used N-domain-directed agents target all four mammalian isoforms with little selectivity (when evaluated using purified proteins; the mitochondrial membrane proton gradient impedes cellular access of many Hsp90 inhibitors to Trap1). Of note, the recently developed inhibitor TAS116 targets only Hsp90 $\alpha$  and Hsp90 $\beta$  (Ohkubo et al 2015). Finally, Paracelsus' tenet that "all things are poison, and nothing is without poison, the dosage alone makes it so a thing is not a poison" (Paracelsus 1538) also applies to off-target effects of the drugs discussed here.

The extent to which individual Hsp90 inhibitors have been tested for off-target effects varies enormously and is often not apparent from publications. To the best of our knowledge, few if any have been thoroughly tested with modern target profiling methods (Blagg and Workman 2014; see also below). The pioneering Hsp90 inhibitor GA and its derivatives have naturally been most closely scrutinized. Although these agents are no longer in clinical development, they are frequently used as a benchmark for confirming

Hsp90 inhibition. GA and its derivatives, as the first small molecule Hsp90 inhibitors to be identified, have clearly been instrumental in demonstrating that Hsp90 is druggable, that its pharmacologic inhibition provides a significant means to unravel chaperone function and to identify its protein clientele, while also demonstrating that Hsp90 inhibition *in vivo* is not only feasible but is surprisingly well tolerated (Trepel et al 2010). However, moving forward we suggest that it is preferable to place a greater emphasis on use of second generation synthetic Hsp90 inhibitors in order to confirm Hsp90 dependence of a particular cellular activity, for the reasons mentioned above. For example, several off-target effects are unique to GA and its derivatives and these depend on their chemical nature as benzoquinones. At high concentrations (> 10  $\mu\text{M}$ ), GA induces the production of reactive oxygen species, dependent on the presence of the quinone moiety, whose cytotoxicity can be quenched by scavengers (Dikalov et al 2002; Clark et al 2009; Samuni et al 2010). *In vivo*, the presence of the quinone moiety is responsible for the dose-limiting hepatotoxicity of the benzoquinone Hsp90 inhibitors (Samuni et al 2010). The redox activity of the benzoquinone Hsp90 inhibitors also affects glutathione levels, which in turn could influence many cellular processes (McCollum et al 2006; Lang et al 2007; Mlejnek and Dolezel 2014). Further, GA and its clinical derivative 17-AAG directly bind to the voltage-dependent anion channel (VDAC) of the outer mitochondrial membrane. VDAC was discovered as a GA-binding protein by a pull-down with GA-conjugated beads. Because these natural products target VDAC at relatively low concentrations (0.1 – 1  $\mu\text{M}$ ), the benzoquinone class of Hsp90 inhibitors lead to mitochondrial membrane depolarization and increased intracellular  $\text{Ca}^{2+}$  levels (Xie et al 2011).

Hsp90 is a member of the GHKL superfamily of ATPases/kinases that utilize a common Bergerat fold to bind ATP. In addition to Hsp90, these proteins also include DNA topoisomerase II, the DNA-mismatch-repair enzyme MutL and histidine kinases (Dutta and Inouye 2000). It is therefore possible that some N-domain ATP-competitive Hsp90 inhibitors could target one or more of these important enzymes, and this should be evaluated on a case by case basis. For example, the resorcinol radicicol, but not the benzoquinone GA, inhibits the archeal DNA topoisomerase type IIB (Gadelle et al 2005)

and binds its ATPase domain in a manner equivalent to its binding to Hsp90 (Corbett and Berger 2006). Ironically, novobiocin, another natural product, was initially examined as a potential Hsp90 inhibitor because it was known to interact with the ATP-binding pocket of the bacterial GHKL protein DNA gyrase B (Maxwell 1993). However, novobiocin proved to bind to the C-terminal region of Hsp90 (Marcu et al 2000a). Nonetheless, novobiocin is not only a potent inhibitor of bacterial DNA gyrase B, it inhibits mammalian DNA polymerase  $\alpha$  and topoisomerases I and II (Burke et al 1979; Edenberg 1980; Hussy et al 1986).

Additional off-targets have been reported for radicicol. It inhibits several eukaryotic members of the GHKL family in addition to the archeal DNA topoisomerase IIB. At high concentrations, radicicol also inhibits the yeast Sln1 histidine kinase (Besant et al 2002). Further, radicicol inhibits mammalian citrate lyase (Ki et al 2000) as well as mammalian branched-chain  $\alpha$ -keto acid dehydrogenase kinase and mammalian pyruvate dehydrogenase kinase (PDHK) (Tuganova et al 2001; Kato et al 2007). Indeed, based on this pharmacophore, novel dual inhibitors have been developed that target both Hsp90 and PDHK with remarkable affinities (Meng et al 2014).

The resorcinolic Hsp90 inhibitor AUY922 (Brough et al 2008) has received extensive clinical evaluation (although it is no longer in clinical trials). However, like radicicol, AUY922 inhibits PDHK in the low  $\mu$ M range (Meng et al 2014). While other off-targets have not been reported for this drug, lack of such information in the published record for this and other clinically evaluated Hsp90 inhibitors is a critical concern.

Considering the list of known off-target interaction reported, it seems clear that, at the very least, all members of the GHKL superfamily of proteins should be directly tested for inhibition with any new compound targeting the ATP-binding pocket of Hsp90.

### ***Experimental approaches for the characterization of off-target effects***

The most straightforward approach to determine whether a drug exhibits off-target effects is to eliminate its molecular target or to replace the molecular target with a mutant version that is unable to bind the drug. Any remaining drug effects would have to be off-target. An early example of this approach is the deletion of the genes for immunophilins and calcineurin in budding yeast to assess the genome-wide off-target effects of FK506 and cyclosporin A by gene expression profiling (Marton et al 1998). This was further developed into chemogenomic profiling using yeast deletion libraries, which yields a list of interactions, both on- and off-target, of a given drug with each gene based on a growth assay (Giaever et al 2004). Indeed, this was done only a few years later for the Hsp90 inhibitor macbecin (McClellan et al 2007). With the CRISPR/Cas9 system, single target gene/protein tests or genome-wide screens are now also possible in human cells (Shalem et al 2014; Shalem et al 2015).

However, this approach is difficult in the case of Hsp90, since its multiple isoforms are encoded by different genes. While the two organelle-restricted isoforms, Trap1 and Grp94, are not essential for cell viability (Randow and Seed 2001; Yoshida et al 2013), the cytosolic isoforms are (Borkovich et al 1989; Voss et al 2000; Zou et al 2017). Maintaining at least some expression of one cytosolic isoform is essential in eukaryotes (Borkovich et al 1989; Picard et al 1990; Picard 2012), and the deletion of one may in some cases be compensated by increased expression of the other (Zou et al 2017). This complexity is reduced somewhat for isoform-selective drugs, but most of these have yet to undergo the rigorous testing and validation for specificity described above. In the case of the two cytosolic Hsp90 isoforms, the fundamental problem remains. Hence, it has not been possible so far to generate a eukaryotic biological system, be it yeast, a mammalian cell line or a multicellular organism, without any cytosolic Hsp90. Mammalian cell lines may tolerate transient shRNA- or siRNA-mediated knockdowns of Hsp90, but a residual amount must remain to ensure cell viability and might account for persistent (or even enhanced) drug sensitivity. Obviously, if one is interested in inhibitors of cytosolic Hsp90, both Hsp90 $\alpha$  and Hsp90 $\beta$  have to be considered, i.e. specifically eliminated or reduced to reveal off-target effects. Swapping the endogenous Hsp90 for an inhibitor-resistant point mutant would be a very elegant approach, but our

understanding of the ATP-binding pocket is insufficient to design a mutant that loses inhibitor binding but remains otherwise fully functional. It has been argued that Hsp90 of the nematode *Caenorhabditis elegans* does not bind GA (David et al 2003), but it is not clear whether this also holds true for other Hsp90 inhibitors. *Humicola fuscoatra*, the fungus that produces radicicol, has an amino acid substitution in the ATP binding pocket that makes its Hsp90 a very poor binder for radicicol without affecting GA binding (Prodromou et al 2009). Intriguingly, several Hsp90 point mutants that confer resistance to 17-AAG and radicicol have been isolated by selection in yeast and then transferred into human Hsp90 and human cells; however, they do not seem to map to sites of interactions with the inhibitors and their molecular mechanisms remain incompletely understood (Zurawska et al 2010).

Hence, there is no perfect experiment to identify off-target effects with genetic tools. For human cells, depending on the specific experimental question and isoform selectivity of the drug, comparing the effects of a partial knockdown of both Hsp90 $\alpha$  and Hsp90 $\beta$  with the effects of the pharmacological inhibitor may be an acceptable compromise. This type of experimental argument has been used quite often for single readouts such as the impact on one particular Hsp90 client (see <https://www.picard.ch/downloads/Hsp90facts>). To exclude off-target effects, a broader panel of readouts would have to show the same or very similar results. And that may never happen because the absence of the target (e. g. Hsp90 $\alpha$ ) or even multiple targets cannot be equated with the presence of the drug-inhibited target. The latter may still have some residual or even altered functions. With the terminology commonly applied to hormones, one would say that a drug can be both a partial antagonist and a partial agonist. Differentiating between off-target and partial agonistic effects of a drug may be experimentally challenging.

There is yet another complication that precludes equating the genetically induced long-term absence of the target (e.g., Hsp90) with the more acute presence of an inhibitor. The literature is replete with evidence indicating that the effects of Hsp90 inhibitors are extensively influenced by posttranslational modifications of both Hsp90 and co-

chaperones, by the levels of Hsp90 and co-chaperones, and by the cell state-specific nature of the Hsp90 complex (Kamal et al 2003; Forafonov et al 2008; Holmes et al 2008; Mollapour et al 2010; Mollapour and Neckers 2012; Neckers and Workman 2012; Beebe et al 2013; Mollapour et al 2014; Dunn et al 2015; Zong et al 2015; Oberoi et al 2016; Rodina et al 2016; Woodford et al 2016a; Woodford et al 2016b; Zuehlke et al 2017). This diversity of cellular states cannot be accurately captured by genetic disruption.

Unbiased screens, typically involving gene expression profiling, proteomics or yeast 3-hybrid schemes (Terstappen et al 2007; Rix and Superti-Furga 2009; Chan et al 2010; Chidley et al 2011; Lee and Bogyo 2013), can help in target de-convolution. A particularly exciting recent development exploits label-free proteomics to monitor the impact of a given drug on the thermal stability of all detectable proteins (Savitski et al 2014; Martinez Molina and Nordlund 2016; Leuenberger et al 2017). This approach could potentially even identify indirect effects of a drug acting on non-proteinaceous targets, as long as these ultimately affect proteins.

Whatever the approach taken, a remaining issue is that extrapolating from a given experimental test system to other cell types, tissues, or the whole organism may be problematic. Applied to a clinical setting, this is where the molecular concept of "off-target" gives way to the medical concept of "side-effects". The latter are all unwanted effects of a drug and its metabolites that include both target-related and non target-related effects. In the case of Hsp90, some of these undesirable effects may include the consequences of inhibiting other Hsp90 isoforms, and the results of inhibiting Hsp90 in normal cells and unrelated tissues.

**Activation of Hsf1 by Hsp90 inhibitors: Is it on-target or off-target and should it be used as a pharmacodynamic surrogate of Hsp90 inhibition?**

The molecular mechanisms by which Hsp90 alters the transcriptional activity of Hsf1 are far more complex than the relatively simplistic titration model that remains commonly accepted today. Two decades of work have revealed the inadequacies of this model and argue for a revised, more systems-level conceptualization of how Hsp90 function alters Hsf1 activation state, both directly and indirectly. Activation of the Hsf1-regulated heat-shock response can be driven by compounds acting directly on Hsp90 or by compounds that alter Hsp90 function indirectly by perturbing protein homeostasis in a variety of ways. Conversely, a variety of allosteric inhibitors and modulators of Hsp90/co-chaperone engagement have now been reported to alter Hsp90 function in more selective ways than compounds which bind the N-terminal ATP-binding pocket of Hsp90 (Garg et al 2016). These inhibitors are less prone to perturb overall protein homeostasis and many do not activate Hsf1. As a corollary, the observation that a compound does or does not activate Hsf1 provides little or no evidence that it acts as a direct inhibitor of Hsp90, especially since some inhibitors targeted to the C-terminal domain do and some do not activate Hsf1 (Conde et al 2009; Neef et al 2010; Eskew et al 2011). In the case of novobiocin analogs, this characteristic appears to depend on the size of the amide side chain (Ghosh et al 2016). Lastly, the effects of genetic reduction of Hsp90 levels are not phenocopied by most Hsp90 inhibitors (see above). In particular, N-terminal inhibitors confer a positive gain of function in driving the degradation of most client proteins through recruitment of CHIP (Cyr et al 2002; Xu et al 2002). In contrast, Hsp90 levels can be significantly reduced with genetic techniques without depleting clients or activating Hsf1 (Whitesell et al 2014). Much remains to be learned about the dynamic interplay between the chaperone machinery, exemplified by Hsp90 and the major transcriptional regulator of inducible chaperone expression, Hsf1. What has been learned, however, makes clear that development of new, more realistic mechanistic models to clarify how Hsp90 affects Hsf1 are long overdue.

### ***Lessons learned***

Largely to explain the activation of Hsf1 by Hsp90 inhibitors, a model was proposed decades ago that invokes the existence of a repressive association between Hsf1 and

an Hsp90-containing multi-chaperone complex under basal conditions (Zou et al 1998). Upon exposure to proteotoxic stressors, including Hsp90 inhibitors, these chaperone associations are “titered away” by an increased demand for chaperone assistance in combating protein misfolding. As a result, Hsf1 is released to trimerize and undergo the extensive post-translational modifications associated with acquisition of transcriptional transactivating activity (Anckar and Sistonen 2011). While conceptually satisfying, this simple titration model is no longer adequate to accommodate an ever-expanding body of experimental observations. The most prominent of these are summarized below with admittedly author-biased, far from comprehensive reference to the available literature.

- (1) Alternate, chaperone-independent modes of Hsf1 activation, operating in response to specific stressors are now well described (Anckar and Sistonen 2011).
- (2) Hsp90 is present in great excess of basal requirements making it a relatively poor initial sensor of proteotoxic stress. Under non-stress conditions, its cellular level and chaperoning function can be reduced substantially in many organisms and cell types (both normal and neoplastic) without impairing overall protein homeostasis or activating Hsf1 (Jarosz et al 2010; Karras et al 2017).
- (3) Hsf1 is not localized to the cytoplasm, but rather the nucleus in the majority of human tumors and cancer cell lines that have been examined (Mendillo et al 2012).
- (4) In *Xenopus* oocytes, Hsf1 is predominantly localized to the nucleus under basal conditions. Treatment with the classical Hsp90 inhibitor GA under non-stress conditions does not activate Hsf1, but rather impairs activation of a heat-shock reporter in these cells (Ali et al 1998; Bharadwaj et al 1999).
- (5) Hsp90 association with Hsf1 has been demonstrated primarily by introducing recombinant protein into reticulocyte lysate or by cross-linking in intact cells (Zou et al 1998). While the association may have functional significance, it is quite weak. Furthermore, evidence for *in vitro* reconstitution of Hsf1::Hsp90 interaction is remarkably limited. In contrast, robust association of Hsf1 with Hsp70 is readily detected without resort to recombinant proteins or cross-linkers (Shi et al 1998; Taipale et al 2014; Zheng et al 2016).

- (6) In addition to repressing activation-associated Hsf1 oligomerization, a role for Hsp90-containing complexes has been reported for removing Hsf1 trimers from their association with DNA and attenuating Hsf1 transactivating activity (Guo et al 2001; Conde et al 2009).
- (7) Biochemical evidence indicates that Hsp90 $\beta$  can actually potentiate Hsf1 activation (Hentze et al 2016).
- (8) Unlike most clients that are conformationally stabilized by Hsp90 and depleted by N-terminal Hsp90 inhibitors, Hsf1 is not (Anckar and Sistonen 2011).
- (9) Treatment of cells with Hsp90 inhibitors results in modest activation of Hsf1 relative to the extent they compromise Hsp90 function. A number of explanations have been suggested including the destabilization of Hsp90 client proteins (kinases and co-regulators) that are required for robust activation of Hsf1 (Whitesell and Lindquist 2009).
- (10) Hsp90 has far reaching effects on gene expression, including that of heat-shock genes only some of which are mediated by Hsf1. Non-Hsf1 dependent effects may be mediated by other sequence-specific transcription factors, chromatin remodeling factors and elements of the basal transcriptional machinery (Calderwood and Neckers 2016).
- (11) The transcriptional regulation of most heat shock protein genes is complex, often involving input from not just Hsf1 but other transcription factors as well, such as NRF2, NF $\kappa$ B, AP1 and YY1 in a stress- and cell-type-specific manner (Mendillo et al 2012). Given this reality, the ability of a compound under investigation to increase the level of one or more heat shock protein levels is not sufficient evidence to conclude that the increase is indeed mediated *via* Hsf1.
- (12) Many thiol-reactive electrophilic compounds have been reported that exert significant oxidative stress in a concentration-dependent manner that can independently alter both Hsp90 and Hsf1 function (Santagata et al 2012).

### ***Remodeling considerations***

The observations described above highlight the complex relationship between Hsp90 function and Hsf1 activation state. The biology is much more complicated than originally conceived. Indeed, Hsf1 has emerged as a highly networked sensor of protein homeostasis that integrates diverse inputs by multiple mechanisms. Some of these may involve direct or indirect interaction with Hsp90 while others may have little to do with Hsp90 or its chaperone function. As an additional layer of complexity, the Hsf1 regulatory network is context dependent with potential for variation across different organisms, cell types and tissues. As a starting point for discussion, the cartoon presented in Fig. 5 lays out the most prominent factors that need to be considered in developing new, more realistic models for the regulation of Hsf1 activity. In the realm of chaperone-targeted drug development efforts, more realistic models are unlikely to diminish the value of the heat-shock response as a biomarker for heat shock-active drugs of known mechanism (even though such an effect may be unwanted in the context of cancer, see below). In the realm of drug discovery, however, the complexity of Hsf1 activation mechanisms precludes any value to use of the heat shock-response in establishing the proximal target of action for putative inhibitors of Hsp90 or other chaperones.

## **Should the clinical development of Hsp90 inhibitors for cancer treatment be re-focused?**

### ***Design flaws of Hsp90-targeted clinical trials***

Eighteen Hsp90 inhibitors have entered clinical development as anticancer agents during the last 20 years, but only a few remain under active clinical investigation. There are several possible reasons for failure to obtain the robust preclinical activity observed in mouse xenograft models. Some factors that may have contributed to the inability thus far to bring an Hsp90 inhibitor to regulatory approval relate to the pharmacodynamic markers of target engagement used in most Hsp90 clinical trials. The most common

cells analyzed for biomarkers have been peripheral blood mononuclear cells (PBMCs). It is understandable why this tumor surrogate cell population has been favored; in patients with locally advanced or metastatic cancer it is very difficult to obtain biopsies pre- and post-therapy, while obtaining peripheral blood samples pre- and post-therapy is almost always feasible. There are, however, several reasons why PBMCs are not an optimal surrogate tissue for Hsp90 inhibitor clinical trials. First, the pharmacokinetics of Hsp90 inhibitors differs significantly between tumor and normal tissue (Xu et al 2003; Chiosis and Neckers 2006). In addition, certain tumor cells appear to be more sensitive to N-terminal Hsp90 inhibitors than are normal cells (Kamal et al 2003; Woodford et al 2016b). As reported by Kamal et al. (Kamal et al 2003), the Hsp90 complex in cancer cells is biochemically distinct from non-transformed cells, contributing to a high affinity binding state for certain Hsp90 inhibitors. More recently, Chiosis and colleagues have reported that in approximately 50% of cancers, especially in MYC-driven tumors, Hsp90 and Hsc70 can act as scaffolds for functionally integrated complexes they term the epichaperome, which can confer sensitivity to Hsp90 inhibitors (Moulick et al 2011; Rodina et al 2016).

An additional reason why PBMCs are not optimal as a PD surrogate tissue is that many of the most sensitive Hsp90 client proteins are putative tumor drivers that are not expressed in PBMCs, including ALK fusion proteins and HER2. Indeed, the most frequently monitored PD endpoint in PBMCs is Hsp70 induction, which is mediated at the transcriptional level by Hsf1. Unfortunately, and as discussed above, Hsf1 activation is a poor surrogate for on-target *in vivo* activity of an Hsp90 inhibitor. Further, Hsf1 in tumors is thought to contribute to malignancy (Dai et al 2007; Mendillo et al 2012), and its stimulation by high dose Hsp90 inhibitors is likely to contribute to drug resistance. In addition, inhibition of a significant portion of Hsp90 is likely to impact protein homeostasis markedly, engendering upregulation of other components of the PN in the tumor, including Hsf1. Thus, treating to the maximum tolerated dose, a common feature of all Hsp90 inhibitor clinical trials to date, is very likely to be counterproductive with respect to anti-tumor activity. In contrast, preclinical evidence supports administration of a chronic low level, non-heat shock response-inducing concentration of Hsp90 inhibitor

combined with other cytotoxic or targeted therapy may provide an effective strategy to inhibit the emergence of resistance (Whitesell et al 2014). This strategy may also take advantage of the recognized property of Hsp90 inhibitors to accumulate in tumors and to persist for a significantly greater time compared to normal tissues (Eiseman et al 2005; Daozhen et al 2007).

### ***Nuclear functions of Hsp90***

Another factor that may contribute to the less than expected clinical activity of Hsp90 inhibitors is the many roles played by Hsp90 in mediating numerous cellular processes beyond stabilization of oncogenic kinases and the pathways they drive. For example, there is an ever expanding number of critical nuclear events affected by Hsp90 (Trepel et al 2010), including transcriptional regulation, RNA polymerase II pausing (Sawarkar et al 2012), mRNA splicing (Lu et al 2015; Ferraldeschi et al 2016), and induction of apoptosis (Solier et al 2012). As recently proposed by Sawarkar and Paro, the depth and breadth of the Hsp90 interactome, which is frequently updated in a database of interactors maintained by Didier Picard at the University of Geneva (<https://www.picard.ch/Hsp90Int/index.php>), suggests that in addition to direct involvement in chromatin, there exists a cohort of Hsp90 interactors among RNA processing/splicing proteins and DNA replication/damage-response proteins. Thus, Hsp90 may functionally coordinate processes such as the DNA damage response, mRNA splicing, DNA replication, transcription and nuclear architecture (Sawarkar and Paro 2013). Little to no consideration of possible impact of Hsp90 inhibitors on these processes is evident in the design of many preclinical studies, as well as past and current clinical trials evaluating these agents.

### ***Hsp90 and host immunity***

Finally, the vast majority of preclinical models used to evaluate Hsp90 inhibitors rely on mice with compromised immune systems. Thus, the impact of these agents on host immunity and the consequences of that impact on anti-tumor activity have not been

rigorously evaluated. In fact, *in vitro* data suggest that Hsp90 inhibition achieved by conventional dosing is immunosuppressive (Graner 2016). It is surprising therefore, that little has been published on the impact of Hsp90 inhibitors on either the tumor microenvironment or on systemic immunity (Proia and Kaufmann 2015). As of this writing, a single trial sponsored by Emory University that is not yet open for recruitment proposes to combine a checkpoint inhibitory antibody with the Hsp90 inhibitor XL-888 (<https://clinicaltrials.gov/ct2/show/NCT03095781>). An additional Hsp90-related consideration with relevance to anticancer immunity involves the concept of immunogenic cell death (ICD). It has become clear that tumor cells can die in a manner that limits the development of antitumor immunity by inducing tolerance. In contrast, cell death under circumstances that give rise to increased tumor cell surface expression of Hsp90, Hsp70 and calreticulin, as well as secretion of ATP and HMGB1, can lead to induction of adaptive immunity and immunologic memory (Galluzzi et al 2017). Many years ago, heat stress was shown to stimulate the later form of cell death (Feng et al 2001). Since heat stress and Hsp90 inhibition share significant molecular consequences, appropriately dosed Hsp90 inhibitors may also promote ICD, but this remains to be examined. It is critical to understand how to make therapy less toleragenic and to enhance anticancer immunity, with the goal of inducing a sustained systemic antitumor response. It is likely that knowledge gained of the role of Hsp90 in, and the impact of Hsp90 inhibitors on the ICD process will greatly enhance the utility of targeting Hsp90 as a component of a multipronged therapeutic regimen.

### ***Future clinical prospects***

In summary, while several N-terminal Hsp90 inhibitors remain in clinical development, a re-imagining of how to achieve their optimal benefit in cancer patients is urgently needed. To date, emphasis has been placed on impacting client protein levels (with a primary focus on oncogenic kinases), while other critical but more complex activities of Hsp90 that may be associated with the malignant phenotype have not been taken into account in understanding clinical response. Perhaps consideration should be given to employing Hsp90 inhibitors as modulators of central signaling hubs including

transcriptional control, epigenetic state and maintenance of DNA integrity. Such a re-orientation of Hsp90 inhibitor usage would likely lead to investigating different types of tumors and ultimately selecting different agents for combination. Further, dosing strategies must be reconsidered to avoid global disruption of cellular proteostasis and activation of compensatory components of the PN, including Hsf1, while providing enough sustained low-level Hsp90 inhibitor exposure to limit development of resistance to other co-administered anticancer drugs. Lastly, a better understanding of the dose-dependent impact of Hsp90 inhibitors on host systemic immunity and the tumor microenvironment may facilitate productive combination of Hsp90 inhibitors with immunotherapies.

## Conclusions

From the preceding discussion, it is clear that target validation and determination of off-target effects are both critical components of Hsp90 inhibitor development, whether the inhibitor is destined for use as a bioprobe of Hsp90 function or for clinical use in cancer or other diseases. We have assembled a rich toolbox of approaches that can be used for this purpose (see Box 1). Although some may not be applicable in individual cases, we strongly recommend that several orthogonal techniques be used for on-target validation and for identifying promiscuous off-target effects. The later sections of this commentary have focused on re-imagining the way that Hsp90 inhibitors may be used clinically. While most of our focus has been on cancer, it should be clear from our remarks that Hsp90 inhibition may have a useful role in targeting other diseases as well. In each case, one must be cognizant of compensatory responses of the PN to Hsp90 inhibition and of the concept that moderate inhibition *in vivo* may be preferable to maximally tolerated inhibition. In going forward, we must understand that Hsp90 inhibitors are likely to behave differently at the organismal level in humans compared to immunocompromised mice. Failure to do so is part of a more general failure so far to investigate in depth the impact of Hsp90 inhibitors on non-oncogene-driven processes, whether they be host immune responses or the relatively unexplored roles of Hsp90 in

the nucleus. As Hsp90 inhibitors are increasingly applied to non-cancer indications, these considerations will take on added importance. Finally, without validation of on-target specificity in cells and animals, and absent careful consideration of possibly confounding contributions of inevitable off-target effects, Hsp90 inhibitors will not achieve their full potential, either as probes of chaperone function in complex systems or in their successful application in the clinic.

## References

- Alderson TR, Kim JH, Markley JL (2016) Dynamical structures of Hsp70 and Hsp70-Hsp40 complexes. *Structure* 24:1014-1030.
- Ali A, Bharadwaj S, O'Carroll R, Ovsenek N (1998) HSP90 interacts with and regulates the activity of heat shock factor 1 in *Xenopus* oocytes. *Mol Cell Biol* 18:4949-4960.
- Allan RK, Mok D, Ward BK, Ratajczak T (2006) Modulation of chaperone function and cochaperone interaction by novobiocin in the C-terminal domain of Hsp90: evidence that coumarin antibiotics disrupt Hsp90 dimerization. *J Biol Chem* 281:7161-7171.
- Anckar J, Sistonen L (2011) Regulation of HSF1 function in the heat stress response: implications in aging and disease. *Annu Rev Biochem* 80:1089-1115.
- Beebe K, Mollapour M, Scroggins B et al (2013) Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors. *Oncotarget* 4:1065-1074.
- Besant PG, Lasker MV, Bui CD, Turck CW (2002) Inhibition of branched-chain  $\alpha$ -keto acid dehydrogenase kinase and Sln1 yeast histidine kinase by the antifungal antibiotic radicicol. *Mol Pharmacol* 62:289-296.
- Bharadwaj S, Ali A, Ovsenek N (1999) Multiple components of the HSP90 chaperone complex function in regulation of heat shock factor 1 *In vivo*. *Mol Cell Biol* 19:8033-8041.
- Blagg J, Workman P (2014) Chemical biology approaches to target validation in cancer. *Curr Opin Pharmacol* 17:87-100.
- Borkovich KA, Farrelly FW, Finkelstein DB, Taulien J, Lindquist S (1989) Hsp82 is an essential protein that is required in higher concentrations for growth of cells at higher temperatures. *Mol Cell Biol* 9:3919-3930.
- Boyault C, Zhang Y, Fritah S et al (2007) HDAC6 controls major cell response pathways to cytotoxic accumulation of protein aggregates. *Genes Dev* 21:2172-2181.

- Brough PA, Aherne W, Barril X et al (2008) 4,5-diarylisoaxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. *J Med Chem* 51:196-218.
- Buchner J, Grallert H, Jakob U (1998) Analysis of chaperone function using citrate synthase as nonnative substrate protein. *Methods Enzymol* 290:323-338.
- Burke JF, Duff PM, Pearson CK (1979) Effect of drugs on deoxyribonucleic acid synthesis in isolated mammalian cell nuclei. Comparison with partially purified deoxyribonucleic acid polymerases. *Biochem J* 178:621-626.
- Calderwood SK, Neckers L (2016) Hsp90 in cancer: transcriptional roles in the nucleus. *Adv Cancer Res* 129:89-106.
- Chan CT, Reeves RE, Geller R et al (2012) Discovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjects. *Proc Natl Acad Sci USA* 109:E2476-2485.
- Chan JN, Nislow C, Emili A (2010) Recent advances and method development for drug target identification. *Trends Pharmacol Sci* 31:82-88.
- Chidley C, Haruki H, Pedersen MG, Muller E, Johnsson K (2011) A yeast-based screen reveals that sulfasalazine inhibits tetrahydrobiopterin biosynthesis. *Nat Chem Biol* 7:375-383.
- Chiosis G, Lucas B, Huezio H, Solit D, Basso A, Rosen N (2003) Development of purine-scaffold small molecule inhibitors of Hsp90. *Curr Cancer Drug Targets* 3:371-376.
- Chiosis G, Neckers L (2006) Tumor selectivity of Hsp90 inhibitors: the explanation remains elusive. *ACS Chem Biol* 1:279-284.
- Clark CB, Rane MJ, El Mehdi D, Miller CJ, Sachleben LR, Jr., Gozal E (2009) Role of oxidative stress in geldanamycin-induced cytotoxicity and disruption of Hsp90 signaling complex. *Free Rad. Biol. Med.* 47:1440-1449.
- Conde R, Belak ZR, Nair M, O'Carroll RF, Ovsenek N (2009) Modulation of Hsf1 activity by novobiocin and geldanamycin. *Biochem Cell Biol* 87:845-851.
- Corbett KD, Berger JM (2006) Structural basis for topoisomerase VI inhibition by the anti-Hsp90 drug radicicol. *Nucleic Acids Res* 34:4269-4277.

- Crowe LB, Hughes PF, Alcorta DA et al (2017) A fluorescent Hsp90 probe demonstrates the unique association between extracellular Hsp90 and malignancy *in vivo*. ACS Chem Biol 12:1047-1055.
- Cyr DM, Hohfeld J, Patterson C (2002) Protein quality control: U-box-containing E3 ubiquitin ligases join the fold. Trends Biochem Sci 27:368-375.
- Dai C, Whitesell L, Rogers AB, Lindquist S (2007) Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 130:1005-1018.
- Daozhen C, Lu L, Min Y, Xinyu J, Ying H (2007) Synthesis of (131)I-labeled-[(131)I]iodo-17-allylamino-17-demethoxy geldanamycin ([[(131)I]iodo-17-AAG) and its biodistribution in mice. Cancer Biother. Radiopharm. 22:607-612.
- David CL, Smith HE, Raynes DA, Pulcini EJ, Whitesell L (2003) Expression of a unique drug-resistant Hsp90 ortholog by the nematode *Caenorhabditis elegans*. Cell Stress Chaperones 8:93-104.
- Dikalov S, Landmesser U, Harrison DG (2002) Geldanamycin leads to superoxide formation by enzymatic and non-enzymatic redox cycling. J Biol Chem 277:25480-25485.
- Duerfeldt AS, Peterson LB, Maynard JC et al (2012) Development of a Grp94 inhibitor. J Am Chem Soc 134:9796-9804.
- Dunn DM, Woodford MR, Truman AW et al (2015) c-Abl mediated tyrosine phosphorylation of Aha1 activates its co-chaperone function in cancer cells. Cell Rep 12:1006-1018.
- Dutta R, Inouye M (2000) GHKL, an emergent ATPase/kinase superfamily. Trends Biochem Sci 25:24-28.
- Eccles SA, Massey A, Raynaud FI et al (2008) NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 68:2850-2860.
- Edenberg HJ (1980) Novobiocin inhibition of simian virus 40 DNA replication. Nature 286:529-531.
- Eiseman JL, Lan J, Lagattuta TF, Hamburger DR, Joseph E, Covey JM, Egorin MJ (2005) Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[[2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17

- SCID mice bearing MDA-MB-231 human breast cancer xenografts. *Cancer Chemother. Pharmacol.* 55:21-32.
- Eskew JD, Sadikot T, Morales P et al (2011) Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells. *BMC Cancer* 11:468.
- Fadden P, Huang KH, Veal JM et al (2010) Application of chemoproteomics to drug discovery: identification of a clinical candidate targeting hsp90. *Chem Biol* 17:686-694.
- Feng H, Zeng Y, Whitesell L, Katsanis E (2001) Stressed apoptotic tumor cells express heat shock proteins and elicit tumor-specific immunity. *Blood* 97:3505-3512.
- Ferraldeschi R, Welti J, Powers MV et al (2016) Second-generation Hsp90 inhibitor onalespib blocks mRNA splicing of androgen receptor variant 7 in prostate cancer cells. *Cancer Res* 76:2731-2742.
- Forafonov F, Toogun OA, Grad I, Suslova E, Freeman BC, Picard D (2008) p23/Sba1p protects against Hsp90 inhibitors independently of its intrinsic chaperone activity. *Mol Cell Biol* 28:3446-3456.
- Fritah S, Col E, Boyault C et al (2009) Heat-shock factor 1 controls genome-wide acetylation in heat-shocked cells. *Mol Biol Cell* 20:4976-4984.
- Gadelle D, Bocs C, Graille M, Forterre P (2005) Inhibition of archaeal growth and DNA topoisomerase VI activities by the Hsp90 inhibitor radicicol. *Nucleic Acids Res* 33:2310-2317.
- Galam L, Hadden MK, Ma Z, Ye Q-Z, Yun B-G, Blagg BSJ, Matts RL (2007) High-throughput assay for the identification of hsp90 inhibitors based on Hsp90-dependent refolding of firefly luciferase. *Bioorg Med Chem* 15:1939-1946.
- Galluzzi L, Buque A, Kepp O, Zitvogel L, Kroemer G (2017) Reply: The complement system is also important in immunogenic cell death. *Nat. Rev. Immunol.* 17:143.
- Garg G, Khandelwal A, Blagg BS (2016) Anticancer inhibitors of Hsp90 function: beyond the usual suspects. *Adv Cancer Res* 129:51-88.
- Gewirth DT (2016) paralog specific Hsp90 inhibitors - a brief history and a bright future. *Curr Top Med Chem* 16:2779-2791.

- Ghosh S, Liu Y, Garg G, Anyika M, McPherson NT, Ma J, Dobrowsky RT, Blagg BS (2016) Diverging novobiocin anti-cancer activity from neuroprotective activity through modification of the amide tail. *ACS Med Chem Lett* 7:813-818.
- Giaever G, Flaherty P, Kumm J et al (2004) Chemogenomic profiling: identifying the functional interactions of small molecules in yeast. *Proc Natl Acad Sci USA* 101:793-798.
- Graner MW (2016) HSP90 and immune modulation in cancer. *Adv Cancer Res* 129:191-224.
- Grenert JP, Sullivan WP, Fadden P et al (1997) The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation. *J Biol Chem* 272:23843-23850.
- Guo Y, Guettouche T, Fenna M, Boellmann F, Pratt WB, Toft DO, Smith DF, Voellmy R (2001) Evidence for a mechanism of repression of heat shock factor 1 transcriptional activity by a multichaperone complex. *J Biol Chem* 276:45791-45799.
- He H, Zatorska D, Kim J et al (2006) Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. *J Med Chem* 49:381-390.
- Hentze N, Le Breton L, Wiesner J, Kempf G, Mayer MP (2016) Molecular mechanism of thermosensory function of human heat shock transcription factor Hsf1. *eLife* 5:e11576.
- Holmes JL, Sharp SY, Hobbs S, Workman P (2008) Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin. *Cancer Res* 68:1188-1197.
- Hughes PF, Barrott JJ, Carlson DA, Loiselle DR, Speer BL, Bodoor K, Rund LA, Haystead TA (2012) A highly selective Hsp90 affinity chromatography resin with a cleavable linker. *Bioorg Med Chem* 20:3298-3305.
- Hussy P, Maass G, Tümmler B, Grosse F, Schomburg U (1986) Effect of 4-quinolones and novobiocin on calf thymus DNA polymerase  $\alpha$  primase complex, topoisomerases I and II, and growth of mammalian lymphoblasts. *Antimicrob Agents Chemother* 29:1073-1078.

- Immormino RM, Kang Y, Chiosis G, Gewirth DT (2006) Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors. *J Med Chem* 49:4953-4960.
- Jarosz DF, Taipale M, Lindquist S (2010) Protein homeostasis and the phenotypic manifestation of genetic diversity: principles and mechanisms. *Annu Rev Genet* 44:189-216.
- Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ (2003) A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. *Nature* 425:407-410.
- Karras GI, Yi S, Sahni N et al (2017) HSP90 shapes the consequences of human genetic variation. *Cell* 168:856-866 e812.
- Kato M, Li J, Chuang JL, Chuang DT (2007) Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. *Structure* 15:992-1004.
- Ki SW, Ishigami K, Kitahara T, Kasahara K, Yoshida M, Horinouchi S (2000) Radicicol binds and inhibits mammalian ATP citrate lyase. *J Biol Chem* 275:39231-39236.
- Kitson RR, Moody CJ (2013) Learning from nature: advances in geldanamycin- and radicicol-based inhibitors of Hsp90. *J. Org. Chem.* 78:5117-5141.
- Lang W, Caldwell GW, Li J, Leo GC, Jones WJ, Masucci JA (2007) Biotransformation of geldanamycin and 17-allylamino-17-demethoxygeldanamycin by human liver microsomes: reductive versus oxidative metabolism and implications. *Drug Metab. Dispos.* 35:21-29.
- Lee J, Bogoy M (2013) Target deconvolution techniques in modern phenotypic profiling. *Curr Opin Chem Biol* 17:118-126.
- Leuenberger P, Ganscha S, Kahraman A, Cappelletti V, Boersema PJ, von Mering C, Claassen M, Picotti P (2017) Cell-wide analysis of protein thermal unfolding reveals determinants of thermostability. *Science* 355:812.
- Lu Y, Xu W, Ji J et al (2015) Alternative splicing of the cell fate determinant Numb in hepatocellular carcinoma. *Hepatology* 62:1122-1131.
- Ma J, Farmer KL, Pan P, Urban MJ, Zhao H, Blagg BS, Dobrowsky RT (2014) Heat shock protein 70 is necessary to improve mitochondrial bioenergetics and reverse

- diabetic sensory neuropathy following KU-32 therapy. *J. Pharmacol. Exp. Ther.* 348:281-292.
- Marcu MG, Chadli A, Bouhouche I, Catelli M, Neckers LM (2000a) The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. *J Biol Chem* 275:37181-37186.
- Marcu MG, Schulte TW, Neckers L (2000b) Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins. *J Natl Cancer Inst* 92:242-248.
- Martinez Molina D, Nordlund P (2016) The cellular thermal shift assay: a novel biophysical assay for in situ drug target engagement and mechanistic biomarker studies. *Annu Rev Pharmacol Toxicol* 56:141-161.
- Marton MJ, DeRisi JL, Bennett HA et al (1998) Drug target validation and identification of secondary drug target effects using DNA microarrays. *Nat Med* 4:1293-1301.
- Matts RL, Brandt GEL, Lu Y et al (2011a) A systematic protocol for the characterization of Hsp90 modulators. *Bioorg Med Chem* 19:684-692.
- Matts RL, Dixit A, Peterson LB et al (2011b) Elucidation of the Hsp90 C-terminal inhibitor binding site. *ACS Chem Biol* 6:800-807.
- Matts RL, Manjarrez JR (2009) Assays for identification of Hsp90 inhibitors and biochemical methods for discriminating their mechanism of action. *Curr Top Med Chem* 9:1462-1478.
- Maxwell A (1993) The interaction between coumarin drugs and DNA gyrase. *Mol Microbiol* 9:681-686.
- McClellan AJ, Xia Y, Deutschbauer AM, Davis RW, Gerstein M, Frydman J (2007) Diverse cellular functions of the Hsp90 molecular chaperone uncovered using systems approaches. *Cell* 131:121-135.
- McCollum AK, Teneyck CJ, Sauer BM, Toft DO, Erlichman C (2006) Up-regulation of heat shock protein 27 induces resistance to 17-allylamino-demethoxygeldanamycin through a glutathione-mediated mechanism. *Cancer Res* 66:10967-10975.

Mendillo ML, Santagata S, Koeva M et al (2012) HSF1 drives a transcriptional program distinct from heat shock to support highly malignant human cancers. *Cell* 150:549-562.

Meng T, Zhang D, Xie Z et al (2014) Discovery and optimization of 4,5-diarylisoxazoles as potent dual inhibitors of pyruvate dehydrogenase kinase and heat shock protein 90. *J Med Chem* 57:9832-9843.

Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein-tyrosine kinase induced by geldanamycin. *J Biol Chem* 271:22796-22801.

Mlejnek P, Dolezel P (2014) N-acetylcysteine prevents the geldanamycin cytotoxicity by forming geldanamycin-N-acetylcysteine adduct. *Chem Biol Interact* 220:248-254.

Mollapour M, Bourboulia D, Beebe K et al (2014) Asymmetric Hsp90 N domain SUMOylation recruits Aha1 and ATP-competitive inhibitors. *Mol Cell* 53:317-329.

Mollapour M, Neckers L (2012) Post-translational modifications of Hsp90 and their contributions to chaperone regulation. *Biochim Biophys Acta* 1823:648-655.

Mollapour M, Tsutsumi S, Donnelly AC et al (2010) Swe1(Wee1)-dependent tyrosine phosphorylation of Hsp90 regulates distinct facets of chaperone function. *Mol Cell* 37:333-343.

Moulick K, Ahn JH, Zong H et al (2011) Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. *Nat Chem Biol* 7:818-826.

Neckers L, Workman P (2012) Hsp90 molecular chaperone inhibitors: are we there yet? *Clin Cancer Res* 18:64-76.

Neef DW, Turski ML, Thiele DJ (2010) Modulation of heat shock transcription factor 1 as a therapeutic target for small molecule intervention in neurodegenerative disease. *PLoS Biol* 8:e1000291.

Oberoi J, Dunn DM, Woodford MR, Mariotti L, Schulman J, Bourboulia D, Mollapour M, Vaughan CK (2016) Structural and functional basis of protein phosphatase 5 substrate specificity. *Proc Natl Acad Sci USA* 113:9009-9014.

Ohkubo S, Kodama Y, Muraoka H et al (2015) TAS-116, a highly selective inhibitor of heat shock protein 90 $\alpha$  and  $\beta$ , demonstrates potent antitumor activity and minimal ocular toxicity in preclinical models. *Mol Cancer Ther* 14:14-22.

- Picard D (2012) Preface to Hsp90. *Biochim Biophys Acta* 1823:605-606.
- Picard D, Khursheed B, Garabedian MJ, Fortin MG, Lindquist S, Yamamoto KR (1990) Reduced levels of hsp90 compromise steroid receptor action *in vivo*. *Nature* 348:166-168.
- Prodromou C, Nuttall JM, Millson SH et al (2009) Structural basis of the radicicol resistance displayed by a fungal hsp90. *ACS Chem Biol* 4:289-297.
- Prodromou C, Roe SM, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1997) Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone. *Cell* 90:65-75.
- Proia DA, Kaufmann GF (2015) Targeting Heat-Shock Protein 90 (HSP90) as a complementary strategy to immune checkpoint blockade for cancer therapy. *Cancer Immunol. Res.* 3:583-589.
- Randow F, Seed B (2001) Endoplasmic reticulum chaperone gp96 is required for innate immunity but not cell viability. *Nat Cell Biol* 3:891-896.
- Raychaudhuri S, Loew C, Korner R, Pinkert S, Theis M, Hayer-Hartl M, Buchholz F, Hartl FU (2014) Interplay of acetyltransferase EP300 and the proteasome system in regulating heat shock transcription factor 1. *Cell* 156:975-985.
- Rix U, Superti-Furga G (2009) Target profiling of small molecules by chemical proteomics. *Nat Chem Biol* 5:616-624.
- Rodina A, Wang T, Yan P et al (2016) The epichaperome is an integrated chaperome network that facilitates tumour survival. *Nature* 538:397-401.
- Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1999) Structural basis for inhibition of the hsp90 molecular chaperone by the antitumor antibiotics radicicol and geldanamycin. *J Med Chem* 42:260-266.
- Sadikot T, Swink M, Eskew JD et al (2013) Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors. *Assay Drug Dev. Technol.* 11:478-488.
- Samuni Y, Ishii H, Hyodo F, Samuni U, Krishna MC, Goldstein S, Mitchell JB (2010) Reactive oxygen species mediate hepatotoxicity induced by the Hsp90 inhibitor geldanamycin and its analogs. *Free Radic Biol Med* 48:1559-1563.

- Santagata S, Xu YM, Wijeratne EM et al (2012) Using the heat-shock response to discover anticancer compounds that target protein homeostasis. *ACS Chem Biol* 7:340-349.
- Savitski MM, Reinhard FB, Franken H et al (2014) Tracking cancer drugs in living cells by thermal profiling of the proteome. *Science* 346:1255784.
- Sawarkar R, Paro R (2013) Hsp90@chromatin.nucleus: an emerging hub of a networker. *Trends Cell Biol* 23:193-201.
- Sawarkar R, Sievers C, Paro R (2012) Hsp90 globally targets paused RNA polymerase to regulate gene expression in response to environmental stimuli. *Cell* 149:807-818.
- Shalem O, Sanjana NE, Hartenian E et al (2014) Genome-scale CRISPR-Cas9 knockout screening in human cells. *Science* 343:84-87.
- Shalem O, Sanjana NE, Zhang F (2015) High-throughput functional genomics using CRISPR-Cas9. *Nat Rev Genet* 16:299-311.
- Shi J, Van de Water R, Hong K et al (2012) EC144 is a potent inhibitor of the heat shock protein 90. *J Med Chem* 55:7786-7795.
- Shi Y, Mosser DD, Morimoto RI (1998) Molecular chaperones as HSF1-specific transcriptional repressors. *Genes Dev* 12:654-666.
- Soldano KL, Jivan A, Nicchitta CV, Gewirth DT (2003) Structure of the N-terminal domain of GRP94. Basis for ligand specificity and regulation. *J Biol Chem* 278:48330-48338.
- Solier S, Kohn KW, Scroggins B, Xu W, Trepel J, Neckers L, Pommier Y (2012) Heat shock protein 90 $\alpha$  (HSP90 $\alpha$ ), a substrate and chaperone of DNA-PK necessary for the apoptotic response. *Proc Natl Acad Sci USA* 109:12866-12872.
- Stebbins CE, Russo AA, Schneider C, Rosen N, Hartl FU, Pavletich NP (1997) Crystal structure of an Hsp90-geldanamycin complex: targeting of a protein chaperone by an antitumor agent. *Cell* 89:239-250.
- Taipale M, Tucker G, Peng J et al (2014) A quantitative chaperone interaction network reveals the architecture of cellular protein homeostasis pathways. *Cell* 158:434-448.

- Terstappen GC, Schlupen C, Raggiaschi R, Gaviraghi G (2007) Target deconvolution strategies in drug discovery. *Nat Rev Drug Discov* 6:891-903.
- Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. *Nat Rev Cancer* 10:537-549.
- Tuganova A, Yoder MD, Popov KM (2001) An essential role of Glu-243 and His-239 in the phosphotransfer reaction catalyzed by pyruvate dehydrogenase kinase. *J Biol Chem* 276:17994-17999.
- Verba KA, Wang RY, Arakawa A, Liu Y, Shirouzu M, Yokoyama S, Agard DA (2016) Atomic structure of Hsp90-Cdc37-Cdk4 reveals that Hsp90 traps and stabilizes an unfolded kinase. *Science* 352:1542-1547.
- Voss AK, Thomas T, Gruss P (2000) Mice lacking HSP90b fail to develop a placental labyrinth. *Development* 127:1-11.
- Wang Y, Koay YC, McAlpine SR (2017) Redefining the phenotype of Heat Shock Protein 90 (Hsp90) inhibitors. *Chem*. 23:2010-2013.
- Whitesell L, Lindquist S (2009) Inhibiting the transcription factor HSF1 as an anticancer strategy. *Expert Opin Ther Targets* 13:469-478.
- Whitesell L, Santagata S, Mendillo ML, Lin NU, Proia DA, Lindquist S (2014) HSP90 empowers evolution of resistance to hormonal therapy in human breast cancer models. *Proc Natl Acad Sci USA* 111:18297-18302.
- Woodford MR, Dunn DM, Blanden AR et al (2016a) The FNIP co-chaperones decelerate the Hsp90 chaperone cycle and enhance drug binding. *Nat Commun* 7:12037.
- Woodford MR, Truman AW, Dunn DM et al (2016b) Mps1 mediated phosphorylation of Hsp90 confers renal cell carcinoma sensitivity and selectivity to Hsp90 inhibitors. *Cell Rep* 14:872-884.
- Wright L, Barril X, Dymock B et al (2004) Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. *Chem Biol* 11:775-785.
- Xie Q, Wondergem R, Shen Y et al (2011) Benzoquinone ansamycin 17AAG binds to mitochondrial voltage-dependent anion channel and inhibits cell invasion. *Proc Natl Acad Sci USA* 108:4105-4110.
- Xu L, Eiseman JL, Egorin MJ, D'Argenio DZ (2003) Physiologically-based pharmacokinetics and molecular pharmacodynamics of 17-(allylamino)-17-

- demethoxygeldanamycin and its active metabolite in tumor-bearing mice. *J. Pharmacokinet. Pharmacodyn.* 30:185-219.
- Xu W, Marcu M, Yuan X, Mimnaugh E, Patterson C, Neckers L (2002) Chaperone-dependent E3 ubiquitin ligase CHIP mediates a degradative pathway for c-ErbB2/Neu. *Proc Natl Acad Sci USA* 99:12847-12852.
- Ye BX, Deng X, Shao LD et al (2015) Vibsanin B preferentially targets Hsp90 $\beta$ , inhibits interstitial leukocyte migration, and ameliorates experimental autoimmune encephalomyelitis. *J Immunol* 194:4489-4497.
- Yim KH, Prince TL, Qu S, Bai F, Jennings PA, Onuchic JN, Theodorakis EA, Neckers L (2016) Gambogic acid identifies an isoform-specific druggable pocket in the middle domain of Hsp90 $\beta$ . *Proc Natl Acad Sci USA* 113:E4801-4809.
- Yin Z, Henry EC, Gasiewicz TA (2009) (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. *Biochem* 48:336-345.
- Yoshida S, Tsutsumi S, Muhlebach G et al (2013) Molecular chaperone TRAP1 regulates a metabolic switch between mitochondrial respiration and aerobic glycolysis. *Proc Natl Acad Sci USA* 110:E1604-1612.
- Yun BG, Huang W, Leach N, Hartson SD, Matts RL (2004) Novobiocin induces a distinct conformation of Hsp90 and alters Hsp90-cochaperone-client interactions. *Biochem* 43:8217-8229.
- Zheng X, Krakowiak J, Patel N, Beyzavi A, Ezike J, Khalil AS, Pincus D (2016) Dynamic control of Hsf1 during heat shock by a chaperone switch and phosphorylation. *eLife* 5:e18638.
- Zong H, Gozman A, Caldas-Lopes E et al (2015) A hyperactive signalosome in acute myeloid leukemia drives addiction to a tumor-specific Hsp90 species. *Cell Rep* 13:2159-2173.
- Zou J, Guo Y, Guettouche T, Smith DF, Voellmy R (1998) Repression of heat shock transcription factor HSF1 activation by HSP90 (HSP90 complex) that forms a stress-sensitive complex with HSF1. *Cell* 94:471-480.
- Zou M, Bhatia A, Dong H et al (2017) Evolutionarily conserved dual lysine motif determines the non-chaperone function of secreted Hsp90 $\alpha$  in tumour progression. *Oncogene* 36:2160-2171.

Zuehlke AD, Reidy M, Lin C et al (2017) An Hsp90 co-chaperone protein in yeast is functionally replaced by site-specific posttranslational modification in humans. *Nat Commun* 8:15328.

Zurawska A, Urbanski J, Matuliene J, Baraniak J, Klejman MP, Filipek S, Matulis D, Bieganowski P (2010) Mutations that increase both Hsp90 ATPase activity in vitro and Hsp90 drug resistance in vivo. *Biochim Biophys Acta* 1803:575-583.

## Figure legends

**Fig. 1** Hsp90 impacts many components of the cellular PN, including autophagy and the unfolded protein response in the endoplasmic reticulum, as well as cytoplasmic protein quality control and the cytoplasmic stress response.

**Fig. 2** General scheme of the domain structure of Hsp90 and of the target domains of the main classes of Hsp90 inhibitors. ADP and ATP illustrate the importance of the N-terminal domain for ATP binding and hydrolysis; M and C, middle and C-terminal domains; MEEVD, very C-terminal pentapeptide (hallmark of cytosolic Hsp90 isoforms) and binding site for most of the co-chaperones containing tetratricopeptide repeats.

**Fig. 3** The five core scaffold structures common to selective inhibitors of Hsp90 and its paralogs. Specific examples and in some cases the institutional or industrial developer are indicated in parenthesis. Note that ganetespib is a totally synthetic resorcinol analog.

**Fig. 4** Examples of the five core scaffolds of current Hsp90 inhibitors bound in the ATP binding site of Hsp90. PDB designations of these structures are as follows: Ansamycins (GA) 4XDM; Natural Product Resorcinols NP (Radicicol) 4CE1; Synthetic Resorcinols (Ganetespib, Synta) 3TUH; Indanones (SNX-2112; Serenex) HSP902, 4NH7; Tropanones (XL888; Exelixis) 4AWO; Purines (PU-H71; Memorial Sloan-Kettering) 2FWZ.

**Fig. 5** Network-based model for the regulation of Hsf1 by Hsp90. Sentinel references for the interactions depicted are indicated in parentheses (1, Guo et al 2001; 2, Anckar and Sistonen 2011; 3a, Boyault et al 2007; 3b, Raychaudhuri et al 2014; 4, Whitesell and Lindquist 2009; 5, Calderwood and Neckers 2016; 6, Fritah et al 2009).